EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Omega‐3 fatty acids and cardiovascular prevention: is the jury still out?

Christian Hamilton-Craig iD, Karam Kostner, David Colquhoun, Stephen J Nicholls

Internal Medicine Journal · 2023

DOI: 10.1111/imj.16283 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Internal Medicine Journal, 2023. Verfasst von Christian Hamilton-Craig und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Fatty Acids, Omega-3. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cardiovascular benefits of omega‐3 polyunsaturated fatty acids (O3FA) remain a point of confusion in clinical medicine. Recently two large, randomised trials were published with discordant findings regarding the overall benefits of omega‐3 supplementation, resulting in unnecessary confusion and therapeutic nihilism. Epidemiological studies clearly show high intake of fish and measured O3FA (mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) in tissues are inversely associated with cardiovascular events and total mortality. These fatty acids are ‘essential’ and depend almost entirely on intake with very little production from within the body. The efficacy of supplementation depends on background tissue levels, in contradistinction to drug therapy. Insufficient dosing of omega‐3 supplementation using less than 1 g/day and lack of titration to target by failing to measure O3FA levels in the blood may explain these conflicting trial outcomes. We review the current evidence regarding O3FA supplementation and cardiovascular outcomes, describe possible reasons for the discrepant results in the literature including recent controversial data around the mineral oil comparator used in REDUCE‐IT and discuss the potential use of the omega‐3 index to guide management and optimise supplementation in those at greatest risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesFatty Acids, Omega-3AnimalsHumansDietary SupplementsDocosahexaenoic AcidsEicosapentaenoic AcidRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

cardiovascularfish oilomega-3prevention

Substanzen

Docosahexaenoic AcidsEicosapentaenoic AcidFatty Acids, Omega-3

Autor:innen und Institutionen

  • Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • Faculty of Medicine, Griffith University, Sunshine Coast, Queensland, Australia.
  • Director of Cardiology, Mater Hospital, Brisbane, Queensland, Australia.
  • Clinical and Preventive Cardiology, The Wesley Hospital, Brisbane, Queensland, Australia.
  • Victoria Heart Institute, Melbourne, Victoria, Australia.
  • Faculty of Medicine, Monash University, Melbourne, Victoria, Australia.

ORCID-Profile: Christian Hamilton-Craig

Zitieren

APA

Hamilton-Craig, C., Kostner, K., Colquhoun, D., & Nicholls, S. J. (2023). Omega‐3 fatty acids and cardiovascular prevention: is the jury still out?. Internal Medicine Journal. https://doi.org/10.1111/imj.16283

Vancouver

Hamilton-Craig C, Kostner K, Colquhoun D, Nicholls SJ. Omega‐3 fatty acids and cardiovascular prevention: is the jury still out?. Internal Medicine Journal. 2023. doi:10.1111/imj.16283

BibTeX
@article{HamiltonCraig2023,
  author = {Hamilton-Craig, Christian and Kostner, Karam and Colquhoun, David and Nicholls, Stephen J},
  title = {Omega‐3 fatty acids and cardiovascular prevention: is the jury still out?},
  journal = {Internal Medicine Journal},
  year = {2023},
  doi = {10.1111/imj.16283}
}
Kostenlos starten →